Vernal Biosciences Capacity Update May 2024: Cell & Gene Therapy

The journey from discovery to drug product remains complex, often requiring multiple vendors to advance your drug product to clinic. That’s where we come in.

We’re Vernal. The industry’s only seamless, end-to-end mRNA manufacturing platform that sustainably simplifies, de-risks, and accelerates your path from lead identification through candidate selection, IND and market approval. Our integrated technologies and systems enable the manufacturing of high purity drug substance, drug product, and intermediates using phase-appropriate control strategies.

In this presentation from the May 2024 OPCU, we highlight our platform analytical and process technologies designed to accelerate the development of your cell therapy, gene therapy, or vaccine drug product.